Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Abemaciclib shows benefit in dedifferentiated liposarcoma

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC

ASCO 2026: Latest updates in mRCC

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer

ASCO 2026: Breast cancer overview

Bezuclastinib sunitinib combo shows promise in second-line GIST treatment

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?